KALA BIO, Inc.: Form 10-K for the period ended Dec 31, 2022
Filed with the SEC on Mar 3, 2023 and accepted by EDGAR at Mar 3, 2023, 08:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-01-01 to 2022-12-31 | $3.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Selling, general and administrative | 12 months2022-01-01 to 2022-12-31 | $65.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2022-01-01 to 2022-12-31 | −$81.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2022-01-01 to 2022-12-31 | $7.3m | us-gaap:InterestExpense |
| Income tax | 12 months2022-01-01 to 2022-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2022-01-01 to 2022-12-31 | −$44.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2022-01-01 to 2022-12-31 | −$29.48 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2022-01-01 to 2022-12-31 | −$29.48 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2022-01-01 to 2022-12-31 | 1,520,611 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2022-01-01 to 2022-12-31 | −$78.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2022-12-31 | $70.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-12-31 | $85.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-12-31 | $86.8m | us-gaap:Assets |
| Current liabilities | At period end2022-12-31 | $25.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-12-31 | $67.8m | us-gaap:Liabilities |
| Long-term debt | At period end2022-12-31 | $37.9m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-12-31 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2022-12-31 | $19.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-23-002746. Last ingested by Listed: Nov 3, 2026, 19:22 ET. Listed shows no prices and gives no investment advice.